123 related articles for article (PubMed ID: 10217182)
21. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
[TBL] [Abstract][Full Text] [Related]
22. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
[TBL] [Abstract][Full Text] [Related]
23. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
Fisher DC; Vredenburgh JJ; Petros WP; Hussein A; Berry DA; Elkordy M; Rubin P; Gilbert CJ; Peters WP
Bone Marrow Transplant; 1998 Jan; 21(2):117-22. PubMed ID: 9489626
[TBL] [Abstract][Full Text] [Related]
24. Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts.
Vanneaux V; Foïs E; Robin M; Rea D; de Latour RP; Biscay N; Chantre E; Robert I; Wargnier A; Traineau R; Benbunan M; Marolleau J; Socié G; Larghero J
Cytotherapy; 2007; 9(5):508-13. PubMed ID: 17786612
[TBL] [Abstract][Full Text] [Related]
25. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
26. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts.
Behringer D; Bertz H; Schmoor C; Berger C; Dwenger A; Finke J
Bone Marrow Transplant; 1999 Aug; 24(3):295-302. PubMed ID: 10455369
[TBL] [Abstract][Full Text] [Related]
27. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft.
De Souza CA; Durães MI; Vigorito AC; Penteado Aranha FJ; Oliveira GB; De Brito Eid KA; Zulli R; Cristina E; Miranda M; Botega NJ
Haematologica; 2002 Dec; 87(12):1281-5. PubMed ID: 12495902
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic cell transplantation using plasma and DMSO without HES, with non-programmed freezing by immersion in a methanol bath: results in 213 cases.
Hernández-Navarro F; Ojeda E; Arrieta R; Ríos-Rull P; García-Bustos J; Quevedo E; Martín Hernández MP; Jiménez-Yuste V; Rodríguez-Luaces M; López RM; García-Miguel P; Martínez A; Sastre A; Calero F; Gómez-Pastrana F; Martínez B
Bone Marrow Transplant; 1998 Mar; 21(5):511-7. PubMed ID: 9535044
[TBL] [Abstract][Full Text] [Related]
31. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
32. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation.
Friedman J; Lazarus HM; Koç ON
Bone Marrow Transplant; 2000 Oct; 26(8):831-6. PubMed ID: 11081381
[TBL] [Abstract][Full Text] [Related]
33. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
[TBL] [Abstract][Full Text] [Related]
34. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
35. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.
Singhal S; Powles R; Kulkarni S; Treleaven J; Sirohi B; Millar B; Shepherd V; Saso R; Rowland A; Long S; Cabral S; Horton C; Mehta J
Bone Marrow Transplant; 2000 Mar; 25(5):501-5. PubMed ID: 10713626
[TBL] [Abstract][Full Text] [Related]
36. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product.
Calmels B; Lemarié C; Esterni B; Malugani C; Charbonnier A; Coso D; de Colella JM; Deconinck E; Caillot D; Viret F; Ladaique P; Lapierre V; Chabannon C
Transfusion; 2007 Jul; 47(7):1268-75. PubMed ID: 17581163
[TBL] [Abstract][Full Text] [Related]
37. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival.
González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A
Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302
[TBL] [Abstract][Full Text] [Related]
38. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
[TBL] [Abstract][Full Text] [Related]
39. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.
Remberger M; Ringdén O
Transplantation; 2007 Aug; 84(4):551-4. PubMed ID: 17713443
[TBL] [Abstract][Full Text] [Related]
40. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
